In deciding upon a new product or Selleckchem TSA HDAC drug to develop from basic research to clinical practice, researchers generally consider one main factor: does the candidate molecule have translational potential? This question was evaluated by means of six key dimensions on the translational potential of a product (Morgan et al., 2011). After establishing whether the product or translational

medicine has significant potential, one must define the necessary staff for its development. The research team must be comprised of professionals dedicated to prospecting, product development and clinical trials. The members must be multidisciplinary professionals from different fields of scientific knowledge. The

team must be focused on developing products with pre-set targets and attending frequent scientific–academic meetings, where ideas from different viewpoints on the same scenario are discussed. In this case, decisions were reached with the overall purpose of developing an effective fibrin sealant. How is a potential application for a particular selleck inhibitor molecule discovered? At this stage, creative and experienced researchers, who know the research and development laboratory at their institution and have extensive knowledge and keen physician-pharmacist intuition for clinical applications, must integrate and coordinate prospecting teams. These researchers are individuals who can envision promising clinical applications for specific molecules. After

identifying several barriers to performing clinical studies in Brazil, the authors proposed the creation of a Virtual System to Support Clinical Research (SAVPC), called SAVPC, to manage the activities of research subjects, investigators, sponsors and research centres. SAVPC was developed to overcome the barriers described by Beckett et al. (2011) for physician/community participation in clinical research. This context afforded five major actions. SAVPC and all website content followed the ethical principles of the HON Code and were approved by the ERB (Ethics Research PIK3C2G Board) – CEP of the Botucatu Medical School, UNESP. Some of the content was obtained from the National Ethics Council of Brazil, the World Health Organization and the National Institutes of Health. Six main dimensions (Morgan et al., 2011) were crucial for determining the translational potential of fibrin sealant; these are described in Table 1. The final development of the product was accomplished by a research translator (Morgan et al., 2011), an individual responsible for pre-clinical trials and formulation. Thereafter, integration of the research translator with the clinical trial team became crucial to trial design.